[{"id":"8e333d31-cdb1-4edd-a209-db63d88f24e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087263","created_at":"2023-10-17T15:12:53.355Z","updated_at":"2025-02-25T17:26:29.076Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","source_id_and_acronym":"NCT06087263","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SDHB","pipe":" | ","alterations":" KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":" Primary completion: 07/01/2032","primary_completion_date":" 07/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-01-10"},{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"},{"id":"d5162325-5b3c-4d42-94a5-aa1bdf6c5de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839498","created_at":"2021-01-18T18:57:18.296Z","updated_at":"2024-07-02T16:36:02.878Z","phase":"Phase 2","brief_title":"Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma","source_id_and_acronym":"NCT03839498","lead_sponsor":"Columbia University","biomarkers":" SDHB","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/22/2019","start_date":" 01/22/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-10-07"}]